image
Healthcare - Biotechnology - NASDAQ - US
$ 1.305
-1.53 %
$ 119 M
Market Cap
-2.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.3 USD, SELLAS Life Sciences Group, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLS stock under the base case scenario is HIDDEN Compared to the current market price of 1.3 USD, SELLAS Life Sciences Group, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SLS stock under the best case scenario is HIDDEN Compared to the current market price of 1.3 USD, SELLAS Life Sciences Group, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SLS

image
$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-31.5 M OPERATING INCOME
16.78%
-30.9 M NET INCOME
17.30%
-35.4 M OPERATING CASH FLOW
-12.71%
0 INVESTING CASH FLOW
100.00%
46.8 M FINANCING CASH FLOW
109.54%
0 REVENUE
0.00%
-6.92 M OPERATING INCOME
5.61%
-6.74 M NET INCOME
5.22%
-7.15 M OPERATING CASH FLOW
8.37%
0 INVESTING CASH FLOW
0.00%
8 K FINANCING CASH FLOW
-99.96%
Balance Sheet SELLAS Life Sciences Group, Inc.
image
Current Assets 16.3 M
Cash & Short-Term Investments 14 M
Receivables 0
Other Current Assets 2.34 M
Non-Current Assets 3.1 M
Long-Term Investments 0
PP&E 925 K
Other Non-Current Assets 2.18 M
71.97 %12.05 %4.76 %11.22 %Total Assets$19.4m
Current Liabilities 9.51 M
Accounts Payable 3.5 M
Short-Term Debt 544 K
Other Current Liabilities 5.47 M
Non-Current Liabilities 457 K
Long-Term Debt 457 K
Other Non-Current Liabilities 0
35.12 %5.46 %54.84 %4.59 %Total Liabilities$10.0m
EFFICIENCY
Earnings Waterfall SELLAS Life Sciences Group, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 31.5 M
Operating Income -31.5 M
Other Expenses -632 K
Net Income -30.9 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)000(32m)(32m)632k(31m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-326.27% ROE
-326.27%
-158.92% ROA
-158.92%
-301.10% ROIC
-301.10%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis SELLAS Life Sciences Group, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -30.9 M
Depreciation & Amortization 0
Capital Expenditures 0
Stock-Based Compensation 1.56 M
Change in Working Capital -6.65 M
Others -3.95 M
Free Cash Flow -35.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets SELLAS Life Sciences Group, Inc.
image
SLS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership SELLAS Life Sciences Group, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - globenewswire.com - 3 weeks ago
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but inconclusive; the trial continues until 80 patients die, creating investment uncertainty and ongoing cash burn. The company raised $25M in January 2025, extending its runway to late 2025, but may need more funds for regulatory and commercial plans. seekingalpha.com - 1 month ago
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update – Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – globenewswire.com - 1 month ago
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - globenewswire.com - 2 months ago
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 19,685,040 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 19,685,040 shares of common stock in a registered direct offering (the "Offering") at a combined purchase price of $1.27 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.20 per share, will be immediately exercisable upon issuance and will expire 5 years from issuance. globenewswire.com - 3 months ago
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – globenewswire.com - 3 months ago
SELLAS Announces Key Business Objectives for 2025 - Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of “tambiciclib” as Recommended International Nonproprietary Name for SLS009 - - Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML - - Developing SLS009 Pediatric Programs in Hematological and Potentially Other Malignancies - - Company to Host Corporate Update Webinar Today, January 8, 2025, at 9:00 am ET - NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a webinar at 9:00 am ET. “We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,” said Angelos Stergiou, MD, ScD h.c. globenewswire.com - 3 months ago
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia -  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – -  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - -  Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pre-specified threshold of 60 events (deaths) has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), triggering the interim analysis to be conducted by the Independent Data Monitoring Committee (IDMC). The IDMC will conduct a thorough review of the current REGAL data, and the interim analysis will provide an assessment of efficacy, futility as well as safety of GPS. globenewswire.com - 4 months ago
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - globenewswire.com - 4 months ago
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – globenewswire.com - 5 months ago
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – globenewswire.com - 5 months ago
voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS) FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (OTCMKTS: VJTTY) (the ‘Company', ‘voxeljet', or ‘we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, Dressler Group GmbH, and Fraunhofer IPA today announced the successful completion of a material study for waste PA12 powder from laser-based 3D printing systems. In the study, waste powder from Selective Laser Sintering systems was successfully recycled by Dressler Group and. businesswire.com - 5 months ago
8. Profile Summary

SELLAS Life Sciences Group, Inc. SLS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 119 M
Dividend Yield 0.00%
Description SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Contact Times Square Tower, New York, NY, 10036 https://www.sellaslifesciences.com
IPO Date March 12, 2008
Employees 15
Officers Dr. Dragan Cicic M.D., MBA Senior Vice President of Clinical Development Mr. Andrew Elnatan Senior Vice President of Regulatory Affairs, CMC & Quality Ms. Stacy E. Yeung Vice President of Legal Affairs, Head of Compliance & Corporate Secretary Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, President, Chief Executive Officer & Director Mr. John Thomas Burns CPA Senior Vice President & Chief Financial Officer